Zh Nevrol Psikhiatr Im S S Korsakova. 2026;126(1):77-81. doi: 10.17116/jnevro202612601177.
ABSTRACT
OBJECTIVE: To evaluate the clinical manifestations of central sensitization in patients with cerebral small vessel disease (CSVD) (with Fazekas II-III white matter hyperintensity).
MATERIAL AND METHODS: The study included four groups (two test groups and two comparison groups). The test group 1 (TG-Rus) included 50 Russian-speaking patients with a history of CSVD of more than 3 years and a tension and/or cervicogenic headache. The test group 2 (TG-Tat) included 50 Tatar-speaking patients with a history of CSVD of more than 3 years and a tension and/or cervicogenic headache. The comparison groups (CG-Rus and CG-Tat) included 50 Russian-speaking and Tatar-speaking patients with tension and/or cervicogenic headache without CSVD. To assess the central sensitization, the Russian-language and Tatar-language versions of the Central Sensitization Inventory were used.
RESULTS: There were statistically significant differences between the test and comparison groups. Significant differences were found in subclinical central sensitization between the TG-Rus and CG-Rus groups (p=0.002), TG-Tat and CG-Tat groups (p=0.001), pronounced differences between the TG-Rus and CG-Rus groups (p=0.03), TG-Tat and CG-Tat groups (p=0.046), and critical differences between TG-Tat and CG-Tat groups (p=0.046).
CONCLUSION: When providing medical care to patients with CSVD, it is necessary to consider the possible comorbidity of pain syndromes and central sensitization, which can burden the clinical presentation and require a special therapeutic strategy.
PMID:41661013 | DOI:10.17116/jnevro202612601177